Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.
A phase 1, dose-escalating trial was conducted in healthy adults to evaluate immunogenicity and reactogenicity of a type V group B streptococcal (GBS) capsular polysaccharide (CPS)-tetanus toxoid (TT) conjugate vaccine. Participants received one dose of unconjugated V CPS (37 microg), V-TT (2.4 microg CPS/1.1 microg TT), V-TT (9.6 microg CPS/4.3 microg TT) or V-TT (38.5 microg CPS/17.0 microg TT). Each vaccine and all doses of V-TT were well-tolerated. V CPS-specific antibodies reached a peak 4-8 weeks after immunization and were significantly higher through 52 weeks post-immunization in recipients of V-TT at each dose than in uncoupled CPS vaccinees. V-TT vaccine-induced antibodies promoted opsonophagocytic killing of type V GBS and avidity maturation of V CPS-specific IgG.
Baker
Carol J
CJ
Section of Infectious Diseases, Department of Pediatrics, Room 302A, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States. cbaker@bcm.tmc.edu
Rench
Marcia A
MA
Paoletti
Lawrence C
LC
Edwards
Morven S
MS
D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood* / Q000276:immunology; D000915:Antibody Affinity; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D007114:Immunization; D008297:Male; D008875:Middle Aged; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D013290:Streptococcal Infections / Q000517:prevention & control; D022541:Streptococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D013292:Streptococcus agalactiae / Q000276:immunology*; D013745:Tetanus Toxoid / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D016896:Treatment Outcome; D018074:Vaccines, Conjugate / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*
D000907:Antibodies, Bacterial; D011135:Polysaccharides, Bacterial; D022541:Streptococcal Vaccines; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate; C092872:streptococcal polysaccharide-tetanus toxoid conjugate vaccine